Serum Dickkopf-1 as a novel biomarker for hepatocellular carcinoma with stem cell features
AASLD LiverLearning®, Hajime Sunagozaka, 144132
Deregulation of the immune-related transcriptome in Resected human Biliary Tract Cancers
AASLD LiverLearning®, Chiara Braconi, 144133
BAFF, BAFF promoter and BAFF receptor allelic variants in HCV-related Mixed Cryoglobulinemia and Non Hodgkin’s Lymphoma.
AASLD LiverLearning®, Giorgia Ceccotti, 144389
FGF19 immunostaining as biomarker for trial enrichment testing FGFR4 inhibitors in HCC
AASLD LiverLearning®, Agrin Moeini, 144134
Occurrence of polymorphisms and resistant mutations in the NS3, NS5A and NS5B genes of HCV based on sequences deposited in the European Hepatitis C Virus Database (euHCVdb).
AASLD LiverLearning®, DIMAS KLIEMANN, 144390
Patient Derived Organoids can be derived from biopsies of unresectable cholangiocarcinomas and represent an useful tool for functional tumour characterization
AASLD LiverLearning®, Chiara Braconi, 144135
Baseline Immune Changes following DAA Therapy may Predict Early Viral Clearance
AASLD LiverLearning®, Lisa Barrett, 144391
Cost-effectiveness of a risk-stratified hepatocellular carcinoma surveillance strategy in patients with cirrhosis
AASLD LiverLearning®, Yujin Hoshida, 144148
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry
AASLD LiverLearning®, Su Jong Yu, 144149
Quantitative molecular magnetic resonance imaging of fibrogenesis and fat content in the liver during non-alcoholic steatohepatitis
AASLD LiverLearning®, Bryan Fuchs, 144405
Hyperlipidemia and Non-Alcoholic Steatohepatitis are Risk Factors for Hepatocellular Carcinoma Development in the Absence of Cirrhosis
AASLD LiverLearning®, Jennifer Phan, 144150
Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating Sirtuin1expressionin the liver
AASLD LiverLearning®, Chuansheng Wang, 144406
A Human In Vitro Surrogate System For Studying Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Ryan Feaver, 144407
Hepatitis C virus replication promotes p53 degradation through chaperone-mediated autophagy (CMA).
AASLD LiverLearning®, Yucel Aydin, 144164
Among Adults with Hepatocellular Carcinoma in the United States, Low Income Patients Have Significantly Lower Overall Survival Independent of Tumor Stage and Treatment Received
AASLD LiverLearning®, Melissa Yan, 144165
The FXR/TGR5 dual agonist INT-767 prevents and reverses Western diet-induced NASH and modulates major lipid metabolic pathways in mice.
AASLD LiverLearning®, Xiaoxin Wang, 144421
Biological significance of a disintegrin and metalloproteinase 21 expression in hepatocellular carcinoma
AASLD LiverLearning®, Masaaki Takamura, 144166
Reduced PI3K pathway in NK cells of F4-NAFLD patients inhibited mTOR expressions and was correlated with their impaired function
AASLD LiverLearning®, Johnny Amer, 144422
Simultaneous recruitment of Th17 cells in hepatic tissue and in intra-abdominal visceral fat of NASH patients undergoing bariatric surgery
AASLD LiverLearning®, Monika Rau, 144423
Success of Photodynamic Therapy in Palliating Patients With Nonresectable Cholangiocarcinoma: A Meta-Analysis and Systematic Review
AASLD LiverLearning®, Zohair Ahmed, 144180
Up-stage Treatment Migration Improved Overall Survival of Selected BCLC B and C Hepatocellular Carcinoma Patients
AASLD LiverLearning®, POH SENG TAN, 144181
Role of Dietary Fatty Acids in Liver Injury Caused by Vinyl Chloride Metabolites in Mice
AASLD LiverLearning®, Lisanne Anders, 144437
Basic Research Workshop: Program Chair
AASLD LiverLearning®, Mario Strazzabosco, 154677
Impact of age and race/ethnicity for women with gastrointestinal and hepatobiliary malignancies in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144182
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by affecting GLP-1 and gut microbiota
AASLD LiverLearning®, Jian-Gao Fan, 144438
The role of cytochrome P450-2E1 in fast food-induced hepatic fibrosis
AASLD LiverLearning®, Mohamed Abdelmegeed, 144439
Aims of the Workshop
AASLD LiverLearning®, Jorge Bezerra, 154680
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the T reatment of S mall H epatocellular C arcinoma
AASLD LiverLearning®, Huijun Xu, 144196
radiation induced liver disease after stereotactic body radiation therapy for small hepatocellular carcinoma; risk factor and clinical significance
AASLD LiverLearning®, Young Don Kim, 144197
The effects of gut microbiota and the flavin mono-oxygenase enzyme 3 (FMO3) on choline bioavailability in nonalcoholic fatty liver disease
AASLD LiverLearning®, Naim Alkhouri, 144453
Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
AASLD LiverLearning®, Tomokazu Kawaoka, 144198
Serum PEDF is an Independent Indicator of Non-Invasive Diagnosis in Non-Alcoholic Steatoheaptitis
AASLD LiverLearning®, Jingmin Zhao, 144454
NAFLD is Associated with Decreased Oxidation of Orally-Delivered Fatty Acids - a Palmitate Breath Test Study
AASLD LiverLearning®, Gihan Naguib, 144455
Eight weeks treatment duration with Ledipasvir/Sofosbuvir (LDV/SOF) is effective for appropriately selected patients with genotype 1 Hepatitis C virus (HCV) infection: an analysis of multiple real world cohorts totaling >6,500 patients
AASLD LiverLearning®, Vinay Sundaram, 154957
Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases
AASLD LiverLearning®, Susan Bersoff-Matcha, 154958
Hepatobiliary Neoplasia SIG: NASH and HCC: Program Chair
AASLD LiverLearning®, Lopa Mishra, 154703
Retreatment with sofosbuvir + grazoprevir + elbasvir + ribavirin of patients with Hepatitis C virus Genotype 1 or 4 with RASs at failure of a sofosbuvir + ledipasvir or + daclatasvir or + simeprevir regimen (ANRS HC34 REVENGE study)
AASLD LiverLearning®, Victor de Ledinghen, 154959
Human FGF19 but not NGM282, an Engineered Variant of FGF19, Causes Hepatocellular Carcinoma (HCC) In A Diet-Induced Mouse Model of Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lei Ling, 154960
Overview: The Relationship Between NASH and HCC
AASLD LiverLearning®, Hashem El-Serag, 154705
Nucleos(t)ide analogues improved survival of CHB-related HCC patients
AASLD LiverLearning®, wang yun, 144212
Activation of autophagy attenuates alcohol-LPS-induced hepatic steatosis and injury through MD2 associated TLR4 signaling
AASLD LiverLearning®, Wenke Feng, 144468
Patients’ misconceptions about surveillance for hepatocellular carcinoma: Education is needed.
AASLD LiverLearning®, Faydra Lieveld, 144213
Comparison of Obeticholic Acid and GFT505 (Elafibranor) for Treatment of Non-Alcoholic Steatohepatitis (NASH) in a Human In Vitro Surrogate System
AASLD LiverLearning®, Ryan Feaver, 144469
Intrahepatic Cholangiocarcinoma Presenting as LI-RADS 5 'HCC'
AASLD LiverLearning®, Raja Koteswar Dhanekula, 144214
Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment
AASLD LiverLearning®, Charles Theuer, 144471
In vivo knock-down of bile salt export pump exacerbates the homeostasis of the cholesterol and bile acid metabolism in mouse NAFLD model.
AASLD LiverLearning®, Kazuya Okushin, 144472
Endoscopic duodenal mucosal resurfacing (DMR) improves insulin sensitivity, hepatic transaminase levels and anti-inflammatory markers in type 2 diabetes subjects
AASLD LiverLearning®, Harith Rajagopalan, 154973
A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients
AASLD LiverLearning®, Annieke van Baar, 154974
Discovery of new non-invasive tests algorithms (NITs-Algo) for liver disease in subjects with metabolic factors, using SAF scoring system. A proof of concept demonstrating the impact of disease definitions.
AASLD LiverLearning®, Thierry Poynard, 154975
Improvement in NASH histological activity highly correlates with fibrosis regression.
AASLD LiverLearning®, Vlad Ratziu, 154976
Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B
AASLD LiverLearning®, Su Jong Yu, 144228
The sustained virologic response achieved by PegIFN/RBV could significantly improve survival of intermediate stage CHC-HCC patients receiving TACE
AASLD LiverLearning®, Wei Teng, 144229
Roles of CC chemokine receptor 9 in the progression of murine non-alcoholic steatohepatitis
AASLD LiverLearning®, Rei Miyake, 144485
Impact of screening on survival in Hepatocellular Carcinoma patients with Chronic Hepatitis B - A regional U.S. population based study
AASLD LiverLearning®, Rasham Mittal, 144230
Serum Proteomic Biomarkers of Hepatocellular Carcinoma Associated with Nonalcoholic Fatty Liver Diseases in a Newly Established Pig Model
AASLD LiverLearning®, Naohiko Namakura, 144486
3-mercaptopyruvate Sulfurtransferase Exacerbates Nonalcoholic Fatty Liver Disease Via the Inhibition of Hydrogen Sulfide Biosynthesis
AASLD LiverLearning®, Mengchun Li, 144487
EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Favorable Anti-inflammatory and Anti-fibrotic Activity In Vitro
AASLD LiverLearning®, Lijuan Jiang, 144488
DNA methylation level of non-cancerous liver tissue has potential for being a biomarker of multicentric recurrence of hepatocellular carcinoma
AASLD LiverLearning®, Takuji Torimura, 144244
Conditional survival estimate in patients with BCLC stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with or without concurrent radiotherapy
AASLD LiverLearning®, In Rae Cho, 144245
Regional differences in admissions and treatment outcomes for patients with hepatocellular carcinoma (HCC) in Thailand: data from the national universal health care
AASLD LiverLearning®, Ml.Taya Kitiyakara, 144246
Combination treatment of dipeptidyl peptidase IV inhibitor and angiotensin-II type 1 receptor blocker attenuates progression of nonalcoholic steatohepatitis in rats
AASLD LiverLearning®, Shinya Sato, 144502
Oral pentamidine (VLX103) is an effective treatment for high fat diet-induced NASH in mice
AASLD LiverLearning®, Mark Czaja, 144503
Serum YKL-40 as a marker of liver fibrosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
AASLD LiverLearning®, Yohei Mano, 144504
The evaluation of endoplasmic reticulum (ER) stress in steatotic hepatocytes under a new 3D perfusion culture system consistent with hepatic portal blood.
AASLD LiverLearning®, Eiji Kakazu, 144505
Real-life Adherence to BCLC Therapeutic Algorithm of Hepatocellular carcinoma in a Multicenter cohort from Argentina.
AASLD LiverLearning®, Federico Piñero, 144260
The efficacy of radiofrequency ablation combined with transcatheter hepatic chemoembolization for patients with BCLC stage B hepatocellular carcinoma: A multicenter retrospective study-propensity score matching
AASLD LiverLearning®, Masashi Hirooka, 144261
PNPLA3 (rs738409 C>G) contributes to low viral load and decreased risk of hepatocellular carcinoma in HCV genotype 1b cirrhotic patients.
AASLD LiverLearning®, Sona Frankova, 144262
Retinoic acid as a factor in the pathogenesis of NAFLD
AASLD LiverLearning®, Lixin Zhu, 144518
High-Fat Diet Induced Non-Alcoholic Steatohepatitis Impairs Liver Regeneration Post Hepatectomy
AASLD LiverLearning®, S.M.Touhidul Islam, 144519
Body Weight Is a Key Determinant of Alcohol-Induced Shifts in Intestinal Microbial Ecology
AASLD LiverLearning®, Puneet Puri, 144520
B-hydroxybutyrate protects from alcoholic hepatitis via a GPR109a-C/EBPβ dependent pathway
AASLD LiverLearning®, Yonglin Chen, 144521
Disparities associated with out of Region Migration of Liver Transplant Candidates: A Case for Redistricting of UNOS Regions
AASLD LiverLearning®, George Cholankeril, 144276
Portal venous flow measured by ultrasound sonography after percutaneous transhepatic portal vein embolization is useful for prediction of hepatic hypertrophy
AASLD LiverLearning®, Shingo Shimada, 144277
Outcomes of Liver Transplant from Elderly Deceased Donors in the United States
AASLD LiverLearning®, Mica Esquenazi, 144278
Combined Lung and Liver Transplantation Offers Superior Outcomes Compared to Lung Transplantation Alone in Cirrhotics with Portal Hypertension Requiring Lung Transplantation
AASLD LiverLearning®, Jamak Modaresi Esfeh, 144292
Expanding the Utilization of Metabolic Livers for Domino Transplantation: Successful Domino Liver Transplant from a Patient with Propionic Acidemia
AASLD LiverLearning®, Nadia Ovchinsky Nadia, 144293
The Numbers of New Waitlist Registrants and Removals are Outpacing the Number of Liver Transplants: National Trends and Regional Variation from 2003 through 2014
AASLD LiverLearning®, Eric Orman, 144294
Acquired protein C deficiency: a major factor in the hypercoagulable state in patients with cirrhosis.
AASLD LiverLearning®, Armand Abergel, 144308
Outcomes in Patients with Severe Hepatic Encephalopathy and MELD 30 to 34 Justifies Exception to MELD 35 and Higher
AASLD LiverLearning®, George Cholankeril, 144309
Real World Predictors of Hospital Readmission for Hepatic Encephalopathy after Placement of Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Michael Rowley, 144310
Presence of hepatic encephalopathy, without ascites or variceal bleeding, is associated with worse outcomes after elective abdominal surgery
AASLD LiverLearning®, Ameish Govindarajan, 144324
Fecal Microbiota Transplantation from a Rationally Selected Donor is Safe in Patients with Recurrent Hepatic Encephalopathy: Preliminary Data from a Randomized Trial
AASLD LiverLearning®, Jasmohan S. Bajaj, 144325
Good glycemic control contributes to an improvement in hyperammonemia by occlusion of portosystemic shunts in cirrhotic patients with diabetes
AASLD LiverLearning®, Tsuyoshi Ishikawa, 144326
The effect of hepatic arterial buffer response induced by partial splenic embolization on hepatic function in cirrhotic patients by Child-Pugh classification
AASLD LiverLearning®, Ryo Sasaki, 144340
The level of WFA+M2BP levels and alpha-fetoprotein levels are predicted hepatocellular carcinoma after sustained virologic responce with chronic hepatitis C patients
AASLD LiverLearning®, Ken Nishino, 144341
LDV/SOF combination is associated with 100% SVR in patients with thalassemia major: a preliminary report from an Italian multicenter study
AASLD LiverLearning®, Alessandra Mangia, 144342
Hepatic Overexpression of Splicing Regulator Slu7 Ameliorates Alcoholic Steatosis in Mice via Modification of SIRT1 Alternative Splicing
AASLD LiverLearning®, Min You, 144100
T Cell Functionality in Chronic Hepatitis C Patients Treated With the Anti-miR-122 RG-101
AASLD LiverLearning®, Femke Stelma, 144356
Cell Death Biomarkers in Patients with Alcoholic Liver Disease
AASLD LiverLearning®, Benjamin Woolbright, 144101
Reversal of HCV-specific CD8+ T cell exhaustion after removal of cognate antigen
AASLD LiverLearning®, Pierre Tonnerre, 144357
Prediction And Impact Of Alcohol Abstinence After An Episode Of Alcoholic Hepatitis: A Long-Term Follow-Up Study
AASLD LiverLearning®, Jose Altamirano, 144102
Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naïve patients
AASLD LiverLearning®, Sonya MacParland, 144358
Outcomes following index hospitalization with decompensated alcohol-related cirrhosis versus severe alcoholic hepatitis; a retrospective cohort study.
AASLD LiverLearning®, Dev Katarey, 144103
Proteome Dynamics reveals that High Density Lipoprotein Dysfunction in Nonalcoholic Steatohepatitis is related to Increased Degradation of HDL proteins involved in Reverse Cholesterol Transport.
AASLD LiverLearning®, Takhar Kasumov, 144116
The mechanism of lncRNA IFI6 regulation of HCV infection
AASLD LiverLearning®, Xiao Liu, 144372
Impaired Adipocyte Autophagy Promotes White Adipocyte Browning And Protects Against Alcohol-Induced Liver Injury
AASLD LiverLearning®, Wen-Xing Ding, 144117
Plasma cytokines predict faster viral load decline in patients with chronic hepatitis C treated with direct-acting antivirals - an exploratory analysis
AASLD LiverLearning®, Weicheng Wang, 144373
Establishment of a cellular model to study ethanol-induced lipophagy
AASLD LiverLearning®, Xiao-Ming Yin, 144118
Vitamin D antagonizes the expression of genes that are epigenetically regulated by Hepatitis C virus
AASLD LiverLearning®, Ran Tur-Kaspa, 144374
Alcohol Exposure Differentially Regulates Immune Responses of Liver Endothelial Cells and Hepatic Stellate Cells to E. coli Infection
AASLD LiverLearning®, Hugo Rosen, 144119